An observational study in Congenital Heart Defect and Right Ventricular Outflow Tract Reconstruction, sponsored by Queen Fabiola Children's University Hospital. Completed at 1 site in Belgium. Open to participants aged Up to 30 Days. Per ClinicalTrials.gov, last updated 2017-11-20.
Sponsored by Queen Fabiola Children's University Hospital · Observational
Pulmonary homografts are standard substitutes for right ventricular outflow tract reconstruction in congenital heart surgery. Unfortunately shortage and conduit failure secondary to early calcifications and shrinking are observed particularly for small sized conduits in younger patients. In neonates, Contegra® 12mm could be a valuable alternative, but conflicting evidence exists. This retrospective study compared the outcome of these two conduits in a newborn population.
All patients who underwent a right ventricular outflow tract reconstruction between January 1992 and December 2014 at the Hôpital Universitaire des Enfants Reine Fabiola, Belgium
neonatal patients who had a reconstruction of the right ventricular outflow tract with a pulmonary homograft or a Contegra between January 1992 and December 2014 at HUDERF
Exclusion Criteria:
NA
Procedure: right ventricular outflow tract reconstruction with contegra
Procedure: right ventricular outflow tract reconstruction with pulmonary homograft
Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.
cryopreserved pulmonary homografts
Comparison of mid term course between pediatric right ventricular outflow tract recontruction with homograft and contegra
Time frame: up to 195 months post right ventricular outflow tract recontruction
Proportion of early conduit-related reintervention according to the Nakata index
Time frame: up to 195 months post right ventricular outflow tract recontruction
Proportion of early conduit-related reintervention according to the congenital heart defect diagnosis
Time frame: up to 195 months post right ventricular outflow tract recontruction
Proportion of early conduit-related reintervention in right ventricular outflow tract recontructed with contegra
Time frame: up to 195 months post right ventricular outflow tract recontruction
Proportion of early conduit-related reintervention in right ventricular outflow tract recontructed with pulmonary homograft
Time frame: up to 195 months post right ventricular outflow tract recontruction
Overal mortality in right ventricular outflow tract recontructed with contegra
Time frame: up to 195 months post right ventricular outflow tract recontruction
Overal mortality in right ventricular outflow tract recontructed with pulmonary homograft
Time frame: up to 195 months post right ventricular outflow tract recontruction
Residual pulmonary arterial hypertension rate in right ventricular outflow tract recontructed with contegra
Time frame: up to 195 months post right ventricular outflow tract recontruction
Residual pulmonary arterial hypertension rate in right ventricular outflow tract recontructed with pulmonary homograft
Time frame: up to 195 months post right ventricular outflow tract recontruction
Plan to share: No
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Fabiola Children's University Hospital